Replies to post #63020 on Biotech Values

[DewDiligence]

MNTA 2008-2009 News Flow

[Updated entry for Copaxone ANDA.]


3Q08:
Resubmit Lovenox ANDA with immunogenicity info requested by FDA.

2H08:
M118 phase-2a data in stable angina presented at medical conference (probably ASH in Dec 2008).

2H08:
Start M118 phase-2b trial in PCI.

4Q08/1Q09:
FDA action on Lovenox ANDA (assuming resubmission of ANDA in 3Q08).

2H08/1H09:
Partnership deal for M118.

2H08/1H09:
Announcements re FoB program with Sandoz.

2009:
Possible FDA decision on Copaxone ANDA (no formal review schedule).


Let’s talk biotech!
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”